Characterizing Disease Severity, Comorbidities, and Treatment Plans in Pediatric Hidradenitis Suppurativa Patients With and Without Obesity: A Cohort and Cross‐Sectional Analysis
Pediatric Dermatology · 2025
DOI: 10.1111/pde.15983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Dermatology, 2025. Verfasst von Asfia Numani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Pediatric Obesity. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Hidradenitis suppurativa (HS) is a chronic inflammatory condition. While obesity is linked to increased HS severity in adults, data on its impact in pediatric HS remain limited. This study investigates the relationships between obesity, HS severity, HS‐related comorbidities, and therapeutic management in pediatric patients.
Methods
This is a retrospective cohort analysis on patients diagnosed with HS before 18 years of age. Data were collected on disease severity, comorbidity development, and treatments. Trends were compared between HS patients with and without obesity and with healthy controls for comorbidity development.
Results
There was no difference in disease severity using Hurley staging between patients with and without obesity ( p = 0.679). Patients with obesity were more likely to be prescribed biologics ( p = 0.012), but not other treatments. The risk of developing dyslipidemia, anxiety, depression, and thyroid disease was elevated in pediatric HS patients, even after controlling for BMI ( p < 0.001).
Conclusions
In this study, obesity was not associated with HS disease severity in children. However, children with obesity were more likely to be prescribed biologics. HS may independently increase the risk of dyslipidemia, anxiety, depression, and thyroid disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Asfia Numani, Dawn M R Davis
Förderung
- NIGMS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Numani, A., Ziebart, R., Todd, A., Alavi, A., Mohandesi, N. A., & Davis, D. M. R. (2025). Characterizing Disease Severity, Comorbidities, and Treatment Plans in Pediatric Hidradenitis Suppurativa Patients With and Without Obesity: A Cohort and Cross‐Sectional Analysis. Pediatric Dermatology. https://doi.org/10.1111/pde.15983
Vancouver
Numani A, Ziebart R, Todd A, Alavi A, Mohandesi NA, Davis DMR. Characterizing Disease Severity, Comorbidities, and Treatment Plans in Pediatric Hidradenitis Suppurativa Patients With and Without Obesity: A Cohort and Cross‐Sectional Analysis. Pediatric Dermatology. 2025. doi:10.1111/pde.15983
BibTeX
@article{Numani2025,
author = {Numani, Asfia and Ziebart, Rachel and Todd, Austin and Alavi, Afsaneh and Mohandesi, Nessa Aghazadeh and Davis, Dawn M R},
title = {Characterizing Disease Severity, Comorbidities, and Treatment Plans in Pediatric Hidradenitis Suppurativa Patients With and Without Obesity: A Cohort and Cross‐Sectional Analysis},
journal = {Pediatric Dermatology},
year = {2025},
doi = {10.1111/pde.15983}
}
EUVIMED